These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1788747)

  • 1. [The pharmacology of 13,14-dihydro-PGE1 in comparison with PGE1].
    Braun M; Ney P; Hohlfeld T; Szymanski C; Bruch L; Schrör K
    Vasa Suppl; 1991; 33():337-8. PubMed ID: 1788747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man.
    Ney P; Braun M; Szymanski C; Bruch L; Schrör K
    Eicosanoids; 1991; 4(3):177-84. PubMed ID: 1663381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacologic concepts for clinical use of prostaglandin E1].
    Schrör K
    Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PGE0 inhibits collagen and glycosaminoglycan-synthesis in the rabbit arterial wall.
    Rodrigues M; Sinzinger H; Kritz H; Peskar BA; O'Grady J; Rogatti W
    Vasa; 1995; 24(4):333-6. PubMed ID: 8533442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent inhibition of PAF-stimulated human platelets and polymorphonuclear leukocytes by the PGE1 analog OP-1206.
    Hecker G; König E; Ney P; Schrör K
    Prog Clin Biol Res; 1987; 242():317-22. PubMed ID: 2444988
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prostaglandin (PG) E1 and its initial metabolites on neutrophil-induced inhibition of human platelet aggregation.
    Pallapies D; Peskar BA
    Thromb Res; 1993 Aug; 71(3):217-25. PubMed ID: 8211888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance.
    Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA
    Prostaglandins Other Lipid Mediat; 1998 Apr; 55(5-6):265-75. PubMed ID: 9653766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of alpha-naphthyl thiourea-induced lung injury by prostaglandin E1 and platelet depletion.
    Fantone JC; Kunkel RG; Kinnes DA
    Lab Invest; 1984 Jun; 50(6):703-10. PubMed ID: 6233454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
    Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine: possible role of platelet insensitivity to prostaglandin E1 (PGE1).
    Cerneca F; de Luyk S; Radillo O; Simeone R; Mangiarotti M
    Funct Neurol; 1993; 8(6):403-8. PubMed ID: 8150318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathomechanisms of atherosclerosis beneficially affected by prostaglandin E1 (PGE1)--an update.
    Sinzinger H; Virgolini I; Fitscha P
    Vasa Suppl; 1989; 28():6-13. PubMed ID: 2692201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of parenteral lipid emulsion-induced hyperlipidemia on prostaglandin E1 modulation of platelet function.
    Saladino CF; Kosacolsky-Singer C; Fox R; Nethala V; Feffer SE; Jonas EA
    Artery; 1993; 20(6):303-13. PubMed ID: 8010886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
    Chirkov YY; Chirkova LP; Sage RE; Horowitz JD
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):961-6. PubMed ID: 7564342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prostaglandin E1 on platelet attenuation of oxidant-induced edema in isolated rabbit lungs.
    Heffner JE; Baron DA
    J Lab Clin Med; 1990 Dec; 116(6):797-804. PubMed ID: 2246556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PGD2, PGE1, and PGI2-analogues on PGDF-release and aggregation of human gelfiltered platelets.
    Stürzebecher S; Nieuweboer B; Matthes S; Schillinger E
    Prog Clin Biol Res; 1989; 301():365-9. PubMed ID: 2477855
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
    Hesse WH; Rudofsky G; Peskar BA
    Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M; Kazama T; Ikeda T; Sato S
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibition of leukotriene (LT) B4 release from human polymorphonuclear leukocytes (PMN) by the PGE1-analogue OP-1206.
    Ney P; Hecker G; Schröder H; Schrör K
    Biomed Biochim Acta; 1988; 47(10-11):S186-9. PubMed ID: 2470354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.